Google
Trusted Resources: News & Events
Latest announcements and gatherings
Vaso-Occlusive Crisis: The Future of Treating Patients With Sickle Cell Disease in Emergency Departments
Claudia Morris, MD, Childrens Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, has been studying arginine (Arg) as a therapeutic option for sickle cell disease (SCD) for years. Recently, her research revealed groundbreaking findings of the effects of Arg on patients experiencing a vaso-occlusive episode (VOE).
While statistically insignificant, results showed a clinically relevant decrease in total parenteral opioid (TPO) and a shortened time to crisis resolution in both intervention groups treated with Arg compared with placebo. Arginine is approved by the FDA for growth hormone stimulation, and because of that investigators have access to 50 years worth of safety information, despite the lack of use for treating VOEs. “The challenge right now is that we have no therapies in the emergency department to treat acute pain, outside of pain medications and IV opioids,” Morris said.
+myBinderRelated Content
-
Robert H. Broyles, PhDRobert H. Broyles was founder and presid...
-
Nancy Green, MDNancy Green, MD is a pediatric hematolog...
-
SCDAA And MedicAlert Pilot Program ApplicationSCDAA and MedicAlert Pilot Program Impr...
-
Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (...BACKGROUND: Immunogenicity, safety and r...
-
Acute Vaso-Occlusive Pain is Temporally Associated With the Onset of Menstruation in Women With Sickle Cell DiseaseBackground: Acute vaso-occlusive pain e...
-
Sickle cell trait may not increase the risk of deathPeople who carry a gene for sickle cell ...
-
Pediatric sickle cell study stopped early due to positive resultsA national sickle cell disease study inv...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.